TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in patients with platinum-sensitive ovarian cancer.

Brian Riley as President and Chief Technical Officer, Joanne Lager, MD as Chief Medical Officer, and Adrian Chaisson as Chief of Staff.

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for children.

GSK and iTeos Therapeutics agreed to spend $900 million on the global development plan for their TIGIT drug. The asset’s failure in Phase II means GSK and iTeos likely only spent a fraction of that ...